Foray into lab-related business to drive UMediC growth prospects


PETALING JAYA: UMediC Group Bhd’s foray into the lab-related business and sustained demand for medical devices and consumables are expected to drive its growth prospects in the upcoming quarters.

Hong Leong Investment Bank (HLIB) Research said the integrated healthcare supply chain group’s core net profit for the third quarter of financial year 2023 (3Q23) of RM1.7mil was below both its and consensus expectations, accounting for 58% and 63% full year forecasts respectively.

Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Axteria to buy 80% stake in Niaga Sari
TPG said to pick advisers for Asia OneHealthcare sale or IPO
Arka to dispose of 40% interest in Enfrasys Solutions for RM43mil
Energy transition to rely on grid and viability
MTT Shipping IPO oversubscribed ahead of listing
FBM KLCI slips on profit-taking amid ceasefire doubt
CCB disposes of Johor land for RM347mil
Rozali to exit as Puncak Niaga chairman
MCE to acquire 50% stake in FP Project
Govt to explore privatisation of highway projects

Others Also Read